Mankind Pharma — 360° view

Mankind Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹4,338 crore and net profit of ₹716 crore for the September 2026 quarter.

Mankind Pharma (NSE: MANKIND) closed at ₹2,665.00 on 20 Nov 2026, up 19.0% over the past year. Its market capitalisation is ₹1,10,077 crore and it trades at 47.2 times earnings.

Share price
₹2,665.00 (20 Nov 2026)
Market cap
₹1,10,077 Cr (20 Nov 2026)
P/E
47.19 (20 Nov 2026)
Revenue
₹4,338 Cr (September 2026 quarter)
Net profit
₹716 Cr (September 2026 quarter)
ROCE
13.5% (FY26)
ROE
13.1% (FY26)
Book value
₹426 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,705.00 / ₹1,909.70 (20 Nov 2026)
1-year return
19.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: MANKIND

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.